Opportunities Preloader

Please Wait.....

Report

Crohn'S Disease Diagnostics and Therapeutics Market - Growth, Trends, Covid-19 Impact, and Forecasts (2023 - 2028)

Market Report I 2023-01-23 I 113 Pages I Mordor Intelligence

The Crohn's disease diagnostics and therapeutics market is estimated to register a CAGR of 3.1% during the forecast period.

With the rise in COVID-19, the prevalence of other related complications also increased. According to a report by the SECURE-IBD database in January 2022, adverse COVID-19 outcomes were associated with age and other co-morbidities among patients with IBD. The novel severe acute respiratory syndrome-related coronavirus activated innate and adaptive immune responses upon entering the gastrointestinal tract. The study shows IBD patients' inflammatory reactions may cause intestinal damage. Also, a research article published in the Journal of Crohn and Colitis in March 2020 showed that IBD patients undertaking immune suppressors are associated with a greater risk of infections, even though there is no evidence to suggest that COVID-19 affects IBD patients more commonly than the general population. According to a review article in the World Journal of Gastroenterology in October 2020, it was comprehended that many COVID-19 patients were found to develop gastrointestinal complaints. Thus, there is an increasing demand for the Crohn's disease diagnostics and therapeutics market to manage further complications that could develop due to COVID-19.

The increasing occurrence of Crohn's disease is the primary driver predicted to boost the growth of the market. According to a report by the CDC published on World IBD Day in April 2021, the number of people affected by IBD is around 7 million worldwide. The report also stated that the rate of prevalence of the disease significantly increased during the last two decades. The prevalence of chronic health conditions such as cancer, arthritis, migraine, and other cardiovascular, respiratory, kidney, and liver diseases are higher in IBD patients than in non-IBD patients. In the older population (66 years and above), patients with IBD were more susceptible to hospitalization for hip fractures. Also, they were found to have 30-day readmissions, and more extended hospital stays. Studies on the treatment of IBD for the prevention of such instances are a great boost to the development of the market during the forecast period.

The increasing awareness of Crohn's disease, coupled with rising initiatives by regulatory bodies to develop novel treatment options, is expected to provide the market studied with high growth potential.

Crohns Disease Diagnostic & Therapeutic Market Trends

The Anti-inflammatory Agents Segment is Expected to Witness Significant Growth During the Forecast Period

Anti-inflammatory agents have continued to lead as the largest sub-segment under the market's therapeutics segment due to their higher efficacy than immunosuppressants and analgesics. A specific category of anti-inflammatory agents includes non-steroidal anti-inflammatory drugs (NSAIDs). NSAIDs are among the most commonly used medication for Crohn's disease.

Additionally, the increasing investments, clinical trials, and key player activities are expected to contribute to the growth of the segment studied. For instance, in September 2022, rise therapeutics LLC received funding from the National Institute of Diabetes and Digestive and Kidney Diseases at the National Institute of Health to support proof-of-concept clinical testing of the therapeutic candidate, R-3750. It is an anti-inflammatory drug for the treatment of inflammatory bowel disease.

Similarly, in July 2021, Cerecord had positive initial phase 1 b results for CERC-002 in moderate to severe Crohn's disease patients who had previously failed three or more lines of biologic therapies, including anti-TNF alpha treatments. Thus the abovementioned factors are expected to drive the growth of the segment studied during the forecast period.

North America is Expected to Hold a Significant Share in the Market During the Forecast Period

North America holds the largest market share in the Crohn's disease diagnostics and therapeutics market due to the increasing prevalence of the disease in the region. The increasing adoption of innovative medicines is expected to drive the demand for the Crohn's disease diagnostics therapeutics market in the North American region. An increase in research and development in clinical-stage companies in novel treatments for the disease is predicted to boost the growth of the Crohn's disease diagnostics therapeutics market in the region. In a study published in the Lancet journal for Gastroenterology and Hepatology in January 2020, it was found that the prevalence of the disease ranged from 252 to 439 cases per 100,000 population in the United States.

In this region, urbanization is a potential factor contributing to the increasing prevalence of Crohn's disease. The incidence of Crohn's disease has been attributed to the "westernization" of lifestyles, such as changes in diet, smoking, differences in exposure to sunlight, pollution, and industrial chemicals. Also, the growth strategies of market players, such as partnerships, are expected to contribute to the growth of the market in this region. For instance, in January 2022, LifeArc partnered with the US-based Crohn's and Colitis Foundation to develop a prognostic for Crohn's disease in children. Thus the abovementioned factors are expected to drive the growth of the market in this region during the forecast period.

Crohns Disease Diagnostic & Therapeutic Market Competitor Analysis

The Crohn's disease diagnostics and therapeutics market has growth opportunities in developing and developed nations. The competitive landscape includes an analysis of a few international and local companies that hold market shares and are well known. Some major market players include Pfizer Inc., Janssen Biotech Inc., GeneTech, Celgene Corporation, AbbVie Inc., and others.

Additional Benefits:

The market estimate (ME) sheet in Excel format
3 months of analyst support

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Multiple Symptoms Associated with the Disease Requiring Individual Therapeutic Attention
4.2.2 Demand for Prompt Diagnosis
4.2.3 Affected Population Increasing with Time
4.3 Market Restraints
4.3.1 No Specific Treatment or Drug Available in the Market
4.3.2 Lack of Awareness Among People and Symptom Similarity with Other Gastrointestinal Diseases
4.3.3 Lack of Cost-effective Treatment
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Diagnostics
5.1.1 Blood Test
5.1.2 Fecal Test
5.1.3 Colonoscopy
5.1.4 Flexible Sigmoidoscopy
5.1.5 Computerised Tomography
5.1.6 Magnetic Resonance Imaging
5.1.7 Other Diagnostic Tests
5.2 By Treatment
5.2.1 Medication
5.2.1.1 Anti-inflammatory Agents
5.2.1.2 Immunosuppressants
5.2.1.3 Analgesics and Antipyretics
5.2.1.4 Other Medications
5.2.2 Surgery
5.3 By Geography
5.3.1 North America
5.3.1.1 United States
5.3.1.2 Canada
5.3.1.3 Mexico
5.3.2 Europe
5.3.2.1 Germany
5.3.2.2 United Kingdom
5.3.2.3 France
5.3.2.4 Italy
5.3.2.5 Spain
5.3.2.6 Rest of Europe
5.3.3 Asia-Pacific
5.3.3.1 China
5.3.3.2 Japan
5.3.3.3 India
5.3.3.4 Australia
5.3.3.5 South korea
5.3.3.6 Rest of Asia-Pacific
5.3.4 Middle East
5.3.4.1 GCC
5.3.4.2 South Africa
5.3.4.3 Rest of Middle East
5.3.5 South America
5.3.5.1 Brazil
5.3.5.2 Argentina
5.3.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Abbvie Inc.
6.1.2 Celgene Corporation
6.1.3 Genetech
6.1.4 Johnson & Johnson
6.1.5 Pfizer Inc.
6.1.6 Prometheus Laboratories Inc. (Nestle)
6.1.7 Salix Pharmaceuticals Inc. (Valeant Pharmaceuticals)
6.1.8 Takeda's Pharmaceutical Ltd

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $4750.00
  • $5250.00
  • $6500.00
  • $8750.00
  • ADD TO BASKET
  • BUY NOW